Related references
Note: Only part of the references are listed.Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma Effects Across a Broad Range of Eosinophil Counts
Jonathan Corren et al.
CHEST (2016)
Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels A Randomized Phase 3 Study
Leif Bjermer et al.
CHEST (2016)
Efficacy of Reslizumab in Older Patients (≥65 years) with Asthma and Elevated Blood Eosinophils: Results from a Pooled Analysis of Two Phase 3, Placebo-Controlled Trials
David I. Bernstein et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2016)
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials
Mario Castro et al.
LANCET RESPIRATORY MEDICINE (2015)
LATE-BREAKING ABSTRACT: Reslizumab in patients with late-onset asthma with elevated blood eosinophils
Guy Brusselle et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
Reslizumab in children and adolescents with eosinophilic esophagitis: Results of a double-blind, randomized, placebo-controlled trial
Jonathan M. Spergel et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2012)
Share Paper
